DBV Technologies

News

DBV gets peanut allergy therapy programme back on track

Shares in DBV have shot up on phase 3 results that set up a US filing for its peanut allergy therapy. which could plug a looming hole in the market.

News

After FDA snub, DBV charts a new course for Viaskin peanut

It’s been more than three years since DBV Technologies’ peanuty allergy therapy was

News

NICE backs Aimmune's peanut allergy drug Palforzia for child...

Children in England with peanut allergies could be among the first in Europe to get access to Aimmune's oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS Engla

News

DBV craters on FDA’s peanut allergy immunotherapy rejection

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end.

DBV gets peanut allergy therapy programme back on track

After FDA snub, DBV charts a new course for Viaskin peanut

NICE backs Aimmune's peanut allergy drug Palforzia for child...

DBV craters on FDA’s peanut allergy immunotherapy rejection

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

DBV Technologies

Editor's Picks